TY - CHAP
T1 - Hepatitis C-induced hepatocellular carcinoma in the middle east
AU - Al-Busafi, Said A.
AU - AlNaamani, Khalid
N1 - Publisher Copyright:
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2021. All rights reserved.
PY - 2021/9/22
Y1 - 2021/9/22
N2 - Hepatocellular carcinoma (HCC) is an important health problem around the world. It represents >85% of primary liver cancers worldwide. Chronic hepatitis C (CHC) infection is one of the major etiologic factors that cause HCC by producing an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. In general, HCC develops only after many years of hepatitis C virus (HCV) infection. The increased risk is limited to a great extent to patients with cirrhosis or advanced fibrosis. Given the current prevalence of HCV infection in Middle Eastern countries, the incidence and mortality rates of HCC are likely to increment throughout the following 10 years. Therefore, this chapter reviews the epidemiology, pathogenesis, and risk factors of HCV and HCV-related HCC in the Middle East (ME). Besides, the preventive and treatment strategies of HCV-related HCC are discussed individually. The comprehensive understanding of opportunities and limitations for successfully implementing the World Health Organization (WHO) HCV elimination targets by 2030 in the ME will help to develop strategies and plans tailored to each country's needs in this region.
AB - Hepatocellular carcinoma (HCC) is an important health problem around the world. It represents >85% of primary liver cancers worldwide. Chronic hepatitis C (CHC) infection is one of the major etiologic factors that cause HCC by producing an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. In general, HCC develops only after many years of hepatitis C virus (HCV) infection. The increased risk is limited to a great extent to patients with cirrhosis or advanced fibrosis. Given the current prevalence of HCV infection in Middle Eastern countries, the incidence and mortality rates of HCC are likely to increment throughout the following 10 years. Therefore, this chapter reviews the epidemiology, pathogenesis, and risk factors of HCV and HCV-related HCC in the Middle East (ME). Besides, the preventive and treatment strategies of HCV-related HCC are discussed individually. The comprehensive understanding of opportunities and limitations for successfully implementing the World Health Organization (WHO) HCV elimination targets by 2030 in the ME will help to develop strategies and plans tailored to each country's needs in this region.
KW - Cirrhosis
KW - DAA therapy
KW - Hepatitis C
KW - Hepatocellular carcinoma
KW - Middle East
UR - http://www.scopus.com/inward/record.url?scp=85159645727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159645727&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-78737-0_17
DO - 10.1007/978-3-030-78737-0_17
M3 - Chapter
AN - SCOPUS:85159645727
SN - 9783030787363
SP - 259
EP - 297
BT - Liver Cancer in the Middle East
PB - Springer International Publishing
ER -